Oragenics Net Income From Continuing Ops Over Time
| OGEN Stock | USD 0.78 0.06 7.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oragenics Performance and Oragenics Correlation. Oragenics | Build AI portfolio with Oragenics Stock |
Will Biotechnology sector continue expanding? Could Oragenics diversify its offerings? Factors like these will boost the valuation of Oragenics. Anticipated expansion of Oragenics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oragenics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Oragenics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oragenics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Oragenics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Oragenics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oragenics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Oragenics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Oragenics and related stocks such as AIM ImmunoTech, Kala Pharmaceuticals, and Ensysce Biosciences Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIM | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (14.4 M) | (19.1 M) | (19.4 M) | (29 M) | (17.3 M) | (15.6 M) | (16.4 M) |
| KALA | (19.4 M) | (19.4 M) | (19.4 M) | (19.4 M) | (19.4 M) | (16.7 M) | (33.2 M) | (42.2 M) | (66.7 M) | (94.3 M) | (96.2 M) | (142.6 M) | (44.8 M) | (46.4 M) | (38.5 M) | (34.7 M) | (36.4 M) |
| ENSC | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 366 K | 4.3 M | (29.1 M) | (24.2 M) | (12.6 M) | (8 M) | (7.2 M) | (7.5 M) |
| SNGX | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (6.7 M) | (7.8 M) | (3.2 M) | (7.1 M) | (8.9 M) | (9.4 M) | (17.7 M) | (12.6 M) | (13.8 M) | (8.1 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| CANF | (30.8 M) | (30.8 M) | (30.8 M) | (30.8 M) | (24.5 M) | (6.5 M) | (7 M) | (5 M) | (6.6 M) | (9.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (9 M) | (7.9 M) | (9.1 M) | (9.5 M) |
| XBIO | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (14.3 M) | (12.5 M) | (54.2 M) | (3.6 M) | (7.3 M) | (12.8 M) | (10.9 M) | (5.6 M) | (6.6 M) | (4.4 M) | (4 M) | (4.6 M) | (4.8 M) |
| CNSP | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (7.4 M) | (3.9 M) | (9.5 M) | (14 M) | (15.3 M) | (18.6 M) | (14.9 M) | (13.4 M) | (14 M) |
| KZIA | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (3.3 M) | (12.2 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (24.6 M) | (20.5 M) | (26.8 M) | (20.7 M) | (18.6 M) | (19.6 M) |
Oragenics and related stocks such as AIM ImmunoTech, Kala Pharmaceuticals, and Ensysce Biosciences Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Oragenics | OGEN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1990 Main Street, |
| Exchange | NYSE MKT Exchange |
USD 0.78
Check out Oragenics Performance and Oragenics Correlation. To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Oragenics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.